Sir,

We thank the author for the comments.\[[@ref1]\] We agree that there is a possibility of ocular inflammation associated with intravitreal bevacizumab injection. On review of literature, the various manifestations of sporadic and "herd" ocular inflammation secondary to bevacizumab which have been reported are mild to moderate conjunctival hyperemia with Descemet\'s membrane striae,\[[@ref2]\] keratitic precipitates,\[[@ref2]\] anterior chamber cell and flare,\[[@ref2][@ref3]\] hypopyon,\[[@ref2]\] and vitritis.\[[@ref2][@ref3]\] However, exudative retinal detachment (RD) after intravitreal bevacizumab injection has not been reported in the past. It is therefore unlikely to be secondary to intravitreal bevacizumab injection and more suggestive of recurrence of Vogt--Koyanagi--Harada syndrome.

To answer the question raised by the author, five other patients received intravitreal bevacizumab injection from the same bevacizumab vial, but none of them developed any signs of inflammation on follow-up.

We agree that an intravitreal injection produces a micro injury; however, the literature have reports of Vogt--Koyanagi--Harada syndrome after cutaneous injury\[[@ref4]\] and even closed head trauma.\[[@ref5]\] A micro injury at the site of pars plana may release enough uveal melanocytes to trigger an inflammatory response in a genetically susceptible individual. Therefore, we postulated that the exudative RD was due to the reactivation of Vogt--Koyanagi--Harada syndrome rather than an inflammation due to bevacizumab.
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